» Articles » PMID: 35139178

Do Patient-reported Measures of Disease Activity in Rheumatoid Arthritis Vary Between Countries? Results from a Nordic Collaboration

Abstract

Objectives: To investigate whether patient-reported outcomes vary across countries and are influenced by cultural/contextual factors. Specifically, we aimed to assess inter-country differences in tender joint count (TJC), pain and patient's global health assessment (PGA), and their impact on disease activity (DAS28-CRP) in RA patients from five Nordic countries.

Methods: We collected data (baseline, 3- and 12-months) from rheumatology registers in the five countries comprising RA patients starting a first ever MTX or a first ever TNF inhibitor (TNFi). In order to assess the role of context (=country), we separately modelled TJC, pain and PGA as functions of objective variables (CRP, swollen joint count, age, sex, calendar period and disease duration) with linear models. Analyses were performed at each time point and for both treatments. We further assessed the impact of inter-country differences on DAS28-CRP.

Results: A total of 27 645 RA patients started MTX and 19 733 started a TNFi. Crude inter-country differences at MTX start amounted to up to 4 points (28 points scale) for TJC, 10 and 27 points (0-100 scale) for pain and PGA, respectively. Corresponding numbers at TNFi start were 3 (TJC), 27 (pain) and 24 (PGA) points. All differences were reduced at 3- and 12-months, and attenuated when adjusting for the objective variables. The variation in predicted DAS28-CRP across countries amounted to <0.5 units.

Conclusions: Inter-country differences in TJC, pain and PGA are greater than expected based on differences in objective measures, but have a small clinical impact on DAS28-CRP across countries.

Citing Articles

Persistently different patterns of patient's global assessment of health in rheumatoid arthritis are associated with pain and impaired function more than with inflammation: an inception cohort study over 15 years.

Bala V, Hafstrom I, Svensson B, Ajeganova S RMD Open. 2025; 11(1).

PMID: 39842872 PMC: 11784202. DOI: 10.1136/rmdopen-2024-004744.


Inadequate Dietary Nutrient Intake in Patients With Rheumatoid Arthritis in Southwestern Sweden: A Cross-Sectional Study.

Wadell A, Barebring L, Hulander E, Gjertsson I, Lindqvist H, Winkvist A Front Nutr. 2022; 9:915064.

PMID: 35799579 PMC: 9255550. DOI: 10.3389/fnut.2022.915064.

References
1.
Kvien T, Heiberg , Lie E, Kaufmann C, Mikkelsen K, Nordvag B . A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol. 2005; 23(5 Suppl 39):S188-94. View

2.
Agca R, Heslinga S, Rollefstad S, Heslinga M, McInnes I, Peters M . EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016; 76(1):17-28. DOI: 10.1136/annrheumdis-2016-209775. View

3.
Ibfelt E, Sorensen J, Jensen D, Dreyer L, Schiottz-Christensen B, Thygesen P . Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry. Clin Epidemiol. 2017; 9:627-632. PMC: 5713680. DOI: 10.2147/CLEP.S141438. View

4.
Orhan C, Van Looveren E, Cagnie B, Mukhtar N, Lenoir D, Meeus M . Are Pain Beliefs, Cognitions, and Behaviors Influenced by Race, Ethnicity, and Culture in Patients with Chronic Musculoskeletal Pain: A Systematic Review. Pain Physician. 2018; 21(6):541-558. View

5.
Aaltonen K, Ylikyla S, Tuulikki Joensuu J, Isomaki P, Pirila L, Kauppi M . Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology (Oxford). 2017; 56(5):725-735. DOI: 10.1093/rheumatology/kew467. View